{"id":"W3130386910","doi":"10.1016/j.jcin.2020.11.046","title":"Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI","year":2021,"lang":"en","type":"review","venue":"JACC: Cardiovascular Interventions","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; St. Michael's Hospital","funders":"Janssen Pharmaceuticals; National Human Genome Research Institute; Amarin Pharma; Abbott Vascular; GE Healthcare; St. Jude Medical; National Center for Advancing Translational Sciences; Johnson and Johnson; National Institutes of Health; Defence Science Institute; Duke Clinical Research Institute; Eisai; Janssen Scientific Affairs; British Heart Foundation; OrbusNeich; Siemens Medical Solutions USA; Medicines Company; Boston Scientific Corporation; Novartis Pharmaceuticals Corporation; Eli Lilly and Company; Foundation for Cardiovascular Research; Bayer; Gilead Sciences; University of Florida; Medtronic; Abbott Laboratories; CSL Behring; Chiesi Farmaceutici; AstraZeneca; Bristol-Myers Squibb; Scott R. MacKenzie Foundation; Portola Pharmaceuticals; Boehringer Ingelheim; Amgen; Merck","keywords":"Ticagrelor; Conventional PCI; Medicine; Dual (grammatical number); Cardiology; Internal medicine; Percutaneous coronary intervention; Myocardial infarction","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.001173365,0.001398573,0.006952883,0.000645216,0.0002588279,0.0002595178,0.0004459683,0.00102017,0.003814564],"category_scores_gemma":[0.0001534781,0.00117298,0.06088419,0.001130342,0.0002497474,0.0002260597,0.0002284272,0.001206379,0.001087777],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003203347,"about_ca_system_score_gemma":0.0006239279,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002590002,"about_ca_topic_score_gemma":0.000004847333,"domain_scores_codex":[0.9929519,0.001303847,0.001696335,0.001684466,0.001419995,0.0009434154],"domain_scores_gemma":[0.994844,0.0002146227,0.0003566685,0.003644679,0.0004308473,0.000509135],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000414322,0.0005791414,0.0000077006,0.007698769,0.1022141,0.003195385,0.00003844607,0.000005225402,2.704261e-7,0.00007143579,0.001977551,0.8837976],"study_design_scores_gemma":[0.007161055,0.0003528212,0.00003357923,0.0233751,0.02681116,0.002416277,0.00005714736,0.000001489807,0.000009874431,0.000009415049,0.9387163,0.001055792],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000214333,0.9917824,0.001357416,0.0000457629,0.00206149,0.002665384,0.0002664411,0.0003499816,0.001256811],"genre_scores_gemma":[0.0002714076,0.9925045,0.0004301915,0.0001249813,0.001526053,0.00152257,0.001454321,0.0004264808,0.001739524],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9367387,"threshold_uncertainty_score":0.9998764,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1403258687003857,"score_gpt":0.3872493015605913,"score_spread":0.2469234328602056,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}